Zoetis Inc. (NYSE:ZTS) Holdings Lowered by First Horizon Advisors Inc.

First Horizon Advisors Inc. trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 46,329 shares of the company’s stock after selling 1,329 shares during the period. First Horizon Advisors Inc.’s holdings in Zoetis were worth $9,144,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ZTS. Vaughan Nelson Investment Management L.P. purchased a new stake in shares of Zoetis during the third quarter valued at $176,219,000. Alphinity Investment Management Pty Ltd lifted its stake in Zoetis by 214.7% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 824,148 shares of the company’s stock worth $162,662,000 after acquiring an additional 562,259 shares in the last quarter. International Assets Investment Management LLC lifted its stake in Zoetis by 27,671.0% in the 4th quarter. International Assets Investment Management LLC now owns 479,328 shares of the company’s stock worth $94,605,000 after acquiring an additional 477,602 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in Zoetis by 34.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 1,562,044 shares of the company’s stock worth $271,764,000 after acquiring an additional 403,164 shares in the last quarter. Finally, Natixis Advisors L.P. lifted its stake in Zoetis by 53.9% in the 3rd quarter. Natixis Advisors L.P. now owns 941,219 shares of the company’s stock worth $163,753,000 after acquiring an additional 329,543 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.1 %

Shares of NYSE ZTS traded down $0.16 during mid-day trading on Friday, reaching $167.07. 2,977,172 shares of the company traded hands, compared to its average volume of 3,178,449. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The stock has a market cap of $76.41 billion, a PE ratio of 32.95, a price-to-earnings-growth ratio of 2.48 and a beta of 0.86. The company’s fifty day moving average is $169.48 and its two-hundred day moving average is $178.89. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The business had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.31 EPS. On average, analysts expect that Zoetis Inc. will post 5.78 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 1.03%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is currently 34.12%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the sale, the executive vice president now owns 14,800 shares in the company, valued at approximately $2,237,316. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 2,209 shares of company stock valued at $371,293 in the last 90 days. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research analyst reports. The Goldman Sachs Group increased their price objective on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Stifel Nicolaus cut their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Finally, Barclays cut their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average target price of $216.13.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.